poisar

Stocks · News reference

Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ELTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

    Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.

    ELTX
  3. Benzinga Newsdesk

    Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

    Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share

    ELTX